Please assess the completion status of the following clinical trial:

Trial Title: Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. 18 to 50 years of age.~ 2. Willing and able to complete the informed consent process.~ 3. Available for clinic visits through 44 weeks after enrollment.~ 4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.~ 5. Willing to donate blood and mucosal samples to be stored and used for future research.~ 6. In good general health without clinically significant medical history.~ 7. Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) less than or equal to 40 within the 56 days prior to enrollment. Laboratory criteria within 56 days prior to enrollment:~ 8. White Blood Cell (WBC) and differential either within institutional normal range or accompanied by Principal Investigator (PI) or designee approval.~ 9. Platelets = 125,000-500,000/mm\^3.~ 10. Hemoglobin within institutional normal range.~ 11. Creatinine less than or equal to 1.1 x upper limit of normal (ULN).~ 12. Alanine aminotransferase (ALT) less than or equal to 1.25 x ULN.~ 13. Negative for HIV infection by an FDA approved method of detection.~      Criteria applicable to women of childbearing potential:~ 14. Negative result on a human chorionic gonadotropin pregnancy test on day of enrollment before receiving study product.~ 15. Agree to use effective means of birth control from at least 21 days before enrollment through 4 weeks after the last injection.~* EXCLUSION CRITERIA:~Criteria applicable to women of childbearing potential:~1. Breast-feeding or planning to become pregnant through 4 weeks after the last injection.~   Subject has received any of the following:~2. More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment.~3. Blood products within 16 weeks prior to enrollment.~4. Live attenuated vaccines within 4 weeks prior to enrollment.~5. Inactivated vaccines within 2 weeks prior to enrollment.~6. Investigational research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study.~7. Current allergen immunotherapy with antigen injections, unless on maintenance schedule.~8. Current anti-tuberculosis(TB) prophylaxis or therapy.~   Subject has any of the following:~9. Serious reactions to vaccines that preclude receipt of study injections as determined by the investigator.~10. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.~11. Asthma that is not well controlled.~12. Diabetes mellitus (type I or II), with the exception of gestational diabetes.~13. Thyroid disease that is not well controlled.~14. Hypertension that is not well controlled.~15. Evidence of autoimmune disease or immunodeficiency.~16. Idiopathic urticaria within the past year.~17. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.~18. Malignancy that is active or history of malignancy that is likely to recur during the study.~19. Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years.~20. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen.~21. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within 5 years prior to enrollment, a history of suicide plan or attempt.~22. Any medical, psychiatric, or social condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject s ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: DS-Cav1 (50 mcg) (Type: EXPERIMENTAL): DS-Cav1 (50 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection.
- Group 2: DS-Cav1 (50 mcg) + alum (Type: EXPERIMENTAL): DS-Cav1 (50 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection.
- Group 3: DS-Cav1 (150 mcg) (Type: EXPERIMENTAL): DS-Cav1 (150 mcg) administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*The Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection, and for 5 additional subjects who were enrolled to evaluate the safety or immunogenicity of a single vaccine dose.
- Group 4: DS-Cav1 (150 mcg) + alum (Type: EXPERIMENTAL): DS-Cav1 (150 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection.
- Group 5: DS-Cav1 (500 mcg) (Type: EXPERIMENTAL): DS-Cav1 (500 mcg) administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection.
- Group 6:DS-Cav1 (500 mcg) + alum (Type: EXPERIMENTAL): DS-Cav1 (500 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12\*)~\*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete